Genetic defects of the retina or retinal pigment epithelium (RPE) cause a substantial number of sight-imparing or blinding disorders, many of which eventually cause the degeneration and death of the visual cells.\textsuperscript{1,2} Previously considered incurable, some of these retinal diseases can now be treated, at least experimentally, by gene therapy. This new era of retinal therapeutics followed the successful restoration of retinal function in a canine model of \textit{RPE65} Leber congenital amaurosis (LCA) through adeno-associated virus 2 (AAV2) vector-mediated gene augmentation targeting the RPE layer of the eye.\textsuperscript{3} Restoring isomerohydrolase activity in the RPE corrected the retinoid cycle and vision defect. When treated at the predegenerate disease stage, treatment was both effective and permanent, and photoreceptor structure was preserved.\textsuperscript{4,5} Validation studies by other groups in both large\textsuperscript{6} and small\textsuperscript{7} animal models, along with preclinical safety studies in nonhuman primates (NHPs) and dogs,\textsuperscript{8,9} confirmed that the treatment was safe and effective. A further series of detailed studies in patients and animal models established the dependence of human cone photoreceptors on RPE65 isomerase,\textsuperscript{11} determined that the remaining photoreceptors in blind eyes were amenable to treatment,\textsuperscript{12-14} showed that the visual cortex in man and dog was intact and responsive in spite of early blindness,\textsuperscript{15} and developed outcome measures that could be used readily to assess treatment outcomes.\textsuperscript{16,17} These studies were followed by three independent clinical trials showing the treatment to be safe.\textsuperscript{18-21} Since then, additional \textit{RPE65}-LCA clinical trials have been initiated both in academic settings and through commercial entities in the United States and elsewhere (https://clinicaltrials.gov/ct2/results?cond=Leber+congenital+amaurosis&term=RPE6, in the public domain). To date, LCA remains the only blinding genetic disease to be successfully treated in humans.

While the early successes in the treatment of LCA were clearly encouraging, it appears that these gene therapy effects do not last “forever.” Despite functional recovery in treated areas, two studies now have shown continual loss of photoreceptors\textsuperscript{22} with the structural phenotype of treated areas eventually becoming comparable to untreated regions.\textsuperscript{5,23} Similar results were obtained in the canine model when treatment was delayed until degeneration had begun, a situation comparable to what occurs in human patients.\textsuperscript{5} This series of discoveries at the level of a human clinical trial indicates there can be unexpected pitfalls even in the most well thought through studies. The \textit{RPE65} gene therapy trials show that even when there is strong evidence of efficacy early after treatment, it cannot be assumed that it will be long lasting. The same care given to defining efficacy in the short term should be used to define the longevity of the treatment success. Thus it is important to emphasize the need to properly assess the treatment outcomes in relation to the natural history of the disease before claiming the success of a putative treatment.

In this overview, I will present concepts and strategies relevant to developing and translating retinal gene therapeutics. These range from selection of the animal model and the therapeutic vector/promoter combination to application of the model system to address translationally relevant questions.

**ANIMAL MODELS**

In vivo studies in animal models are the essential proof-of-concept first step to establish efficacy of a treatment paradigm. In addition to being a bona fide disease homologue, that is, caused by the mutations in the same gene with expression in the same target cell(s), the models should have a proportionally comparable disease time course. Ideally, the model disease should be “fast enough” that the therapeutic outcome can be assessed in a reasonable time scale, but “not too fast and overwhelming” such that efficacy cannot be established and that the disease bears no resemblance to the human disorder. Naturally occurring or genetically engineered models have been the basic toolbox used for examining cellular and molecular mechanisms of gene function and disease, and for developing retinal therapeutics. These animal models cover the size spectrum from \textit{Drosophila} to cow\textsuperscript{25} and horse,\textsuperscript{26} and include all sizes and species in between. In biology and experimental medicine, the models have been arbitrarily divided into large (>dog or cat) and small, with small almost exclusively referring to rodents. As a veterinarian, this division is somewhat ironic given that the model system for my studies is the dog and that in veterinary medicine dogs and cats are considered “small animals.”

For retinal disease studies and for the development and testing of novel therapies, the dog is an ideal intermediate model between mouse and man, as it is well suited to facilitating translational studies. Indeed, in cases where the appropriate model exists, experimental studies in the dog have led the way to clinical trials (\textit{RPE65}-LCA, \textit{CNGB3}-ACHM, and \textit{RPGR}-XLRP), or trials in the late stages for Food and Drug Administration pre-IND (investigational new drugs) application (\textit{BEST}-BVMD) (Table 1). Moreover, with the development and application of new genomic tools, there has been a marked acceleration of disease gene discovery, and a combination of genome-wide association studies (GWAS) along with next-generation sequencing of whole genomes or exomes has facilitated progress in identifying additional genetic models of disease (Fig. 1). The identified mutations affect both the retinal pigment epithelium (RPE) and the rod and/or cone photoreceptors, with defects involving members of the phototransduction cascade, integral outer segment disc proteins, and the
photoreceptor sensory cilium, as well as other structures (for review see Refs. 27, 28). These models represent bona fide human disease homologues where the disease phenotype in model and man are the same. Selected examples include \textit{RPE65}-LCA,\textsuperscript{3,5,29} \textit{BEST1}-BVMD,\textsuperscript{30–32} \textit{CNGB3}-and \textit{CNGA3}-achromatopsia,\textsuperscript{33,34} \textit{RHO}-ADRP,\textsuperscript{35} \textit{RPGR}-XLRP,\textsuperscript{32,36–38} and \textit{NPHP5}-LCA.\textsuperscript{39}

Quite apart from the particular merits of any individual disease model, the dog and the canine eye offer advantages for a broad range of translational studies. Because of its life span and the time course of the diseases, disease progression in the dog more closely resembles that of humans than do similar smaller laboratory animal disease models. Furthermore, as the size of canine and human eyes is similar,\textsuperscript{40} viral vectors or drugs can be injected using the same surgical approaches and dose volumes, and implantation of devices (e.g., retinal prostheses or for sustained delivery of therapeutic agents) is identical to those intended for human trials.\textsuperscript{3,41,42} In addition, the instruments and methods for surgical intervention and in vivo outcome assessments are comparable. Lastly, the recently identified fovea-like region within the canine retina has a similar cone density to the human and nonhuman primate (NHP) fovea, and is equally susceptible to inherited macular diseases, making it an ideal model system to study macular degenerations and therapies.\textsuperscript{32}

It is critical to emphasize, however, that regardless of their translational value, the canine models are not alternatives to other laboratory model systems such as rodents. Rather they are a complementary and synergistic model, serving as an intermediate between rodents and man that provides an excellent test bed to develop or test new therapies. The history of the field clearly demonstrates that progress toward therapy of human patients has been served best by judicious use of a comprehensive set of model systems among which are rodent, canine, and others.

VECTORS, PROMOTERS, AND TRANSLATIONAL APPLICATIONS

A critical issue that must be addressed during development of proof-of-concept gene therapy studies in animal models is to determine whether the results obtained with a vector–promoter combination used in the animal can be directly applied to patients in subsequent clinical trials. While this has been possible in the case of the \textit{RPE65}-LCA, in most cases the vector-
promoter validated in proof-of-concept studies differs when optimized for patients (Supplementary Table S1). Thus, the interplay between vector serotype tropism, promoter, and model species selected has to be considered before translation to the clinic is possible.

**Promoters**

Promoters are traditionally selected to limit transgene expression to the target cell population and minimize off-target expression, and are evaluated using reporter genes such as GFP. Obviously, this is most optimal when the promoter selected regulates the same therapeutic transgene, although that is not always possible. Generally, promoters are selected based on two criteria: (1) The endogenous gene regulated by the promoter is selectively expressed in the target cell(s); (2) there is robust expression of a reporter gene in the target cells when regulated by the chosen promoter. In general, the testing of target gene specificity and robustness of different AAV vector serotypes is done in normal retinas, as shown in our studies.52,45,44 or in vitro35 (Supplementary Table S2). Although there are a few notable exceptions,46-48 these studies rarely assess expression of the endogenous gene targeted for promoter selection at the planned treatment stages, or use the promoter/reporter gene combination to confirm specific expression in the affected mutant cells. Thus, the direct application of results obtained in normal retinas to mutants requires a careful leap of faith. Indeed, we previously showed that the human G-coupled receptor kinase 1 (hGRK1) promoter directed expression of a green fluorescent protein (GFP) reporter to rods but not cones in normal canine retinas.43 This observation confirmed earlier studies which implied that candidate promoters should be selected for eventual therapeutic use was the PR1.7 modification to the hGRK1 promoter directs expression of the therapeutic transgene to mutant cones as well as rods, resulting in rescue of function and structure, even at quite advanced disease stages.

Studies from our lab and others have also shown that species-specific differences markedly influence the expression of reporter or therapeutic transgenes (Supplementary Table S2). In developing a therapeutic strategy for CNGB3 achromatopsia, we tested a series of promoters based on the human red cone opsin locus control region.54 In this dichromatic species with a single long wavelength-sensitive (L/M) class of cones and short wavelength-sensitive S-cones,55 the full-length promoter, PR2.1, directed GFP expression to all L/M-cones in normal and CNGB3-mutant retinas48,56 (Fig. 2). In contrast, a chimeric interphotoreceptor retinoid binding protein/G protein subunit alpha transducin 2 (IRBP/GNAT2) promoter expressed GFP in both L/M- and S-cones in the dog (Fig. 2: Supplementary Table S2). However, when tested in murine and NHP (Macaca fascicularis) retinas, the PR2.1 promoter directed GFP expression to the RPE, cones, and rods in the mouse; expression was present but weak in the NHP L/M-cones, and the chimeric IRBP/GNAT2 promoter showed no photoreceptor specificity in NHP retinas.57 The promoter selected for eventual therapeutic use was the PR1.7 modification of the human red cone opsin promoter, which showed robust GFP expression in L/M- and S-cones in NHP as well as in dogs (Komaromy AM, unpublished observations, 2017).

An equally complex situation exists with cell-specific promoters targeting rods and cones. In our lab, we chose the IRBP promoter for RPRG-XLRP gene therapy studies, as it directed GFP expression specifically to rod and cone photoreceptors in normal dog50 and mouse (Lewin AS, unpublished observations, 2011) retinas (Supplementary Table S2; Fig. 2). Unfortunately, this promoter was ineffective in directing GFP expression to foveal or peripheral cones after subretinal administration in two closely related NHP macaque species (Macaca mulatta and M. fascicularis).51 This finding was surprising given that IRBP expression has been detected in rods and cones of the human retina by in situ hybridization.58 A possible explanation for this discrepancy is that the small IRBP promoter contained only 235 bp of the full-length human IRBP promoter59 and may not have all the regulatory elements needed for cone expression in NHP retina. It is likely that careful dissection of the human IRBP promoter will identify sequences that direct expression to NHP rods and cones. However, such studies appear less necessary now, as we have found that the hGRK1 promoter is highly effective in directing expression to rods and both peripheral and central cones in the NHP retina51 (Fig. 2), and in mutant canine retinas60-62 as well.

**Vectors**

The most widely used vectors for retinal gene transfer and therapy have been recombinant AAVs. Each AAV serotype shows tropism for distinct retinal cells in a species- and administration route-dependent manner. These vectors are considered safe and effective, with long-term stability of expression so that most experimental therapy studies require only a single vector administration. Their main limitation is their cargo-carrying capacity, maximal at ~4.7 kb, which makes them unsuitable for use with full-length, large-sized genes, for example, CEPI200, ABCA4, and others.

Of the vectors used for therapy studies in dogs, AAV2 based, and to a lesser extent AAV1 and -4, are used for targeting the RPE, and AAV5, -8, and AAV2tYF for photoreceptors (Supplementary Table S1). However, the vector serotype toolbox is large, and new versions are continually being developed.63,64 Among the new vectors being developed for dog studies are those identified by directed evolution using the canine retina.62 Some newer AAV vectors have single or multiple mutations that replace critical capsid tyrosine residues to enhance nuclear targeting by bypassing ubiquitination and proteasomal degradation.63,64 These vector constructs also can be packaged as self-complementary vectors to avoid delays caused by DNA synthesis, as must occur to generate double-stranded DNA from the single-stranded genome of older AAV vectors; but such modifications further limit their cargo-carrying capacity.65 Self-complementary AAV vectors with capsid modifications have been evaluated in dogs as a means of increasing transduction efficiency and onset of gene expression using GFP reporter or therapeutic genes (see below), and are therapeutically very effective (Aguirre GD, et al. IOVS 2016;57;ARVO E-Abstract 2293). As with promoters, AAV vector serotype selection for proof-of-concept and therapeutic applications is complex. Additionally, for translation to the clinic, experience with vector production protocols by the commercial entity, as well as intellectual property considerations, often directs serotype selection. The complexity in vector selection for experimental studies is illustrated by our own work in dogs using the X-linked retinal degeneration RPRG-XLRP and NPHP5-LCA models. Both diseases are characterized by abnormal photoreceptor development and early degeneration.53,39,67 We have found that an AAV5-hIRBP-hRPRGRIStb vector (Supplementary Table S1) is effective in arresting the degeneration in RPRG-XLRP when treatment is initiated at 6 weeks of age, that is, early disease stage.68 Delaying treatment until the mid and late stages of disease is equally effective and results in long-term preservation of structure and function (see below). However, when the same vector/promoter combination with a NPHP5 therapeutic transgene is used at the same vector dose in the NPHP5-LCA...
model at 7 weeks of age, the treatment is ineffective; efficacy, however, is obtained by a 10-fold increase in dose if administered at 5.7 weeks of age (Aguirre GD, et al. *IOVS* 2016;57:ARVO E-Abstract 2293). Preliminary studies have shown that switching the vector/promoter combination from AAV5-hIRBP- to scAAV8-hGRK1- or scAAV8.C&G.T449V-hGRK1- results in recovery of cone function, and long-term preservation of structure and function when treatment is initiated at early and at mid/late stages of disease (Beltran WA and Aguirre GD, unpublished observations, 2017). These results suggest that for diseases that are genetically distinct but phenotypically similar, the vector/promoter used for the experimental studies may have to be disease specific, and that a hoped-for “universal” vector/promoter useful for a large class of similar diseases is not possible at this time. This complicates further translational applications, at least in the near term, until a sufficient database resource is obtained from animal studies and human clinical trials that will inform on vector/promoter selection.

**CONCEPTS AND STRATEGIES IN RETINAL GENE THERAPY**

Critically, translating findings from the cage to the bedside requires careful interpretation of the preclinical data based on the experimental studies, and a precise determination of how
closely the model disease parallels the human clinical phenotype. This information, along with a careful assessment of the natural history of the patient’s disease, will determine when to treat, where to treat, how to treat, and how and when to evaluate the therapeutic outcome. The studies William Bellet and I have carried out with Samuel G. Jacobson and Artur V. Cideciyan are a valuable illustration of how model systems can be maximized to inform on clinical applications. Examples are studies done in RPE65-LCA, RPGR-XLRB and RHO-ADRP. In this section, I will discuss three issues of relevance to translational applications.

Is Treatment Forever?

The proof-of-concept studies in both dog and mouse models of RPE65-LCA by several groups using different AAV vectors and promoters provided an impetus to finalize all the steps needed for clinical trials (see Supplementary Table S1). In addition to the product being safe and effective, the treatment outcomes all showed stability of functional rescue, and three independent clinical trials were initiated and reported in 2008–2010.18–20

The RPE was a very compelling cellular target for gene therapy, and the RPE65-LCA model is an ideal test bed for the first venture into this therapeutic modality. Firstly, the RPE is a homogeneous monolayer with an extensive apical microvillar network. Administration of vector by subretinal injection brings the vector into close proximity to the extensive RPE cellular processes without the need of crossing additional cellular barriers or the external limiting membrane. Secondly, AAV2 vectors readily target the RPE cells. Thirdly, tissue-specific promoters, for example, VMD2 and RPE65, limit expression to this cell layer; as does the constitutive hybrid CMV/CBA promoter, at least in the dog. Of greatest significance, however, is the dramatic phenotypic change that occurs within a matter of a few weeks following treatment. Before therapy, the animal has searching nystagmus, has incomplete and delayed pupillary responses, and is functionally blind with only limited and poor vision at very high photopic luminances, and the ERG shows absent rod-mediated function and preservation of cone ERG function in the treated eyes, an indication that the therapy was successful, but noninvasive assessment of outer nuclear layer integrity in the treated regions, both by OCT and by histopathology, the treated areas show RPE65 expression and preservation of rod outer segments (Figs. 3IA–D, 3IIA–III). The late-treated dogs show recovery of rod and cone ERG function in the treated eyes, an indication that the therapy was successful, but noninvasive assessment of outer nuclear layer structure showed degeneration that is comparable to that untreated regions (Figs. 3ID, 3IIIB–III). This is similar to the situation occurring in patients treated at the dysfunction/degeneration stage of disease.

The reason(s) for the short-lived positive treatment effect in patients, and in dogs treated at the dysfunction/degeneration stage of disease, is unknown. One group posits that their vector had insufficient potency to provide the required RPE65 enzymatic activity needed for long-term sustained gains in function and preservation of structure. Consequently an optimized AAV5-OPTIRPE65 vector has been developed that reportedly has 300-fold or greater RPE65 enzymatic activity, and now is in clinical trials (NCT02781480) in the United Kingdom. A second group has proposed that the ongoing degeneration in the presence of rescued function emphasizes the need for combinatorial therapies that combine one of several neuroprotective, antiapoptotic, or other agent(s) as adjunct to the specific gene augmentation therapy, and these studies are ongoing. Yet another group questions the findings of the latter study, but have not provided details yet that the cohort of patients treated in their initial clinical trial fail to show progressive degeneration and dysfunction when measured with the same quantitative retinal structure and visual function methods used in the other two trials. What is clear is that in at least two clinical trials, progressive retinal degeneration continues in spite of initial positive treatment effects. The ongoing studies to determine the cause and prevention of this unanticipated finding will be important for managing patients with this disease after treatments are commercialized, as well as informing on the basic biology of retinal diseases in general and the development of future treatments.

What Happens When Treatment Is a Success but the Patient Is Blind: CNTF-Mediated Photoreceptor Deconstruction in CNGB3 Achromatopsia

Two mutations in canine CNGB3 result in very severe loss of cone ERG function and photopic vision. These mutations, a ~500-kb genomic deletion and a missense change, result in an identical clinical phenotype. The disease locus name, cd for cone degeneration, was based on the marked decrease in the number of cones at very late stages of the disease, but does not truly reflect the status of the cone photoreceptor mosaic in the clinical trial patients in two studies showed continual loss of photoreceptors, which, in treated areas, became comparable to untreated regions. Based on the long-term efficacy of treatment in the dog model, the question arose as to whether the discrepant results between man and model result from a unique susceptibility of the human retina associated with the disease or its treatment, or if efficacy depends on the extent of degeneration at the time of treatment. We have examined this question in a cohort of mutant dogs treated unilaterally at the stage of disease when only dysfunction is present (ages: 0.3–2.4 years), and followed noninvasively by ERG and optical coherence tomography (OCT) and terminally by histopathology (ages: 6.9–11.2 years). In parallel, a second cohort of unilaterally treated dogs was examined noninvasively by OCT and ERG after treatment at the dysfunction/degeneration stage of disease (ages: 4.9–6.6 years). Early-treated dogs show recovery of rod and cone function that is sustained and preservation of outer nuclear layer integrity in the treated regions, both by OCT and by histopathology; the treated areas show RPE65 expression and preservation of rod outer segments (Figs. 3IA–D, 3IIA–III). The late-treated dogs show recovery of rod and cone ERG function in the treated eyes, an indication that the therapy was successful, but noninvasive assessment of outer nuclear layer structure showed degeneration that is comparable to that untreated regions (Figs. 3ID, 3IIIB–III). This is similar to the situation occurring in patients treated at the dysfunction/degeneration stage of disease.

The reason(s) for the short-lived positive treatment effect in patients, and in dogs treated at the dysfunction/degeneration stage of disease, is unknown. One group posits that their vector had insufficient potency to provide the required RPE65 enzymatic activity needed for long-term sustained gains in function and preservation of structure. Consequently an optimized AAV5-OPTIRPE65 vector has been developed that reportedly has 300-fold or greater RPE65 enzymatic activity, and now is in clinical trials (NCT02781480) in the United Kingdom. A second group has proposed that the ongoing degeneration in the presence of rescued function emphasizes the need for combinatorial therapies that combine one of several neuroprotective, antiapoptotic, or other agent(s) as adjunct to the specific gene augmentation therapy, and these studies are ongoing. Yet another group questions the findings of the latter study, but have not provided details yet that the cohort of patients treated in their initial clinical trial fail to show progressive degeneration and dysfunction when measured with the same quantitative retinal structure and visual function methods used in the other two trials. What is clear is that in at least two clinical trials, progressive retinal degeneration continues in spite of initial positive treatment effects. The ongoing studies to determine the cause and prevention of this unanticipated finding will be important for managing patients with this disease after treatments are commercialized, as well as informing on the basic biology of retinal diseases in general and the development of future treatments.
first 3 to 4 years of life. Affected dogs have small, abnormal cone ERG responses until ~8 to 10 weeks of age, which then disappear. The absence of cone function persists for the rest of the dog’s life. Presumably, the presence of intact cyclic nucleotide gated channel alpha 3 (CNGA3) protein in these mutant retinas allows for transient formation of functional CNGA3 homotetramer channels, and cone function, albeit abnormal, is present early during development.\(^{1,80}\)

Subretinal injections of a therapeutic transgene (AAV5-PR2.1-bcNGR3) restored ERG cone function and photopic vision in CNGR3 mutants regardless of the mutation class. Long-term assessment in a subset of treated dogs showed that cone flicker was preserved stably for more than 2.5 years following treatment\(^{48}\) (Komaromy AM and Aguirre GD, unpublished observations, 2017; Figs. 4A, 4B). Recovery of cone function following gene therapy was accompanied by the restoration of normal cone phototransduction protein localization to the cone outer segments in treated regions. Specifically, while the cone phototransduction proteins, GNAT2 and CNGA3, were mislocalized from the outer segment to elsewhere in the cone cell in the untreated mutant retinas,\(^{20}\) bCNGR3 augmentation resulted in the proper localization of these proteins in the L/M-cone outer segments.\(^{48}\) (Fig. 4E).

These initial studies established treatment efficacy, and, in concordance with the promoter assessment\(^{26}\) (Supplementary Table S2), confirmed that the PR2.1 promoter was the most
effective in producing a sustained recovery of cone function. The shorter versions of the human red cone opsin promoter, PR0.5 and 3LPR-PHO.5, were not effective in treating young animals; and recovery of cone function either did not occur or was transient, and bCNGB3 transgene expression, in general, was low.48 (Fig. 4C). However, studies using the AAV5-PR2.1-bCNGB3 therapeutic vector did reveal an apparent age-dependent effect in the rescue of cone function. While 11 of 14 eyes recovered cone function when treated at less than 0.5 years of age, only 1 of 3 did so when treatment was initiated after 1 year of age. This absence of functional rescue was not due to cone loss in older retinas as cone loss is gradual, and at 1 year of age the superior central region of the retina, the region targeted for therapy, still retains ~80% and 97%, respectively, of the L/M- and S-cone numbers when compared to control.81 Similarly, treatment failure was not due to inefficient targeting of mutant cones, as bCNGB3 mRNA expression in the “nonrescued” retinas was comparable to or only slightly lower than in successfully treated eyes (Fig. 4C).

In addition, untreated mutant retinas had levels of cone gene expression (CNGB3, CNGA3 [present only in missense mutants], L/M- and S-cone opsins) that were comparable to wild type, an indication that the principal components underlying cone function are not compromised.49 Based on these findings, we posited that treatment failure in these eyes resulted from the inability of the structurally stable mutant cone outer segment to assemble functional CNG channels, despite the expression of both channel subunits after treatment. We further reasoned that if cones could reform an outer segment at the time of treatment, functional channels would be assembled. Such an approach would have required the transient elimination of the cone outer segment structure without permanently impairing their long-term viability and function. This effect can be mediated by ciliary neurotrophic factor (CNTF), and we have used it as a therapeutic adjunct to gene therapy.81

Intravitreal injection of CNTF in the rat retina leads to a marked shortening of the photoreceptor outer segments and decrease in photoreceptor gene expression; maximal effects occur within 3 to 6 days after injection, and are fully reversible within 3 weeks.82 Similarly, intravitreal CNTF in the normal dog retina has a maximal effect by 1 week in terms of decreased rod and cone ERG amplitudes, shortening of rod, S- and L/M-cone outer segments, and rod and cone gene expression. By 5 weeks after treatment the retina returns to normal. As the changes are reversible and photoreceptors transiently become more immature immediately following CNTF, we have termed this process transient photoreceptor deconstruction.83 Although the effects are panretinal and affect rods and cones equally, for the purpose of the CNGB3 gene therapy work, the cell of interest for the effect is the cone.

To determine if CNTF-mediated transient photoreceptor deconstruction would enhance cone functional rescue in older CNGB3 mutant retinas, we injected eyes from older (age range, 1.2–3.5 years) mutant dogs with either 30 μL CNTF (~4–5 μg/mL vitreous) or PBS 7 days prior to a subretinal injection of AAV5-PR2.1-bCNGB3. Significantly, all seven mutant eyes pretreated with CNTF had sustained recovery of cone function following bCNGB3 gene augmentation, an effect that was not found in any of the seven eyes pretreated with PBS81 (Table 2). Quantitative RT-PCR assessment of CNGB3 therapeutic transgene levels indicated comparable expression levels between PBS- and CNTF-pretreated retinas (Fig. 4D). However, only the CNTF-pretreated retinas showed the proper localization of GNAT2 and CNGA3, two cone phototransduction proteins required for normal function, in the L/M-cone outer segments (Fig. 4E); as a specific CNGB3 antibody was not available, the expression of this critical protein and its localization could not be determined.

The achromatopsia gene therapy studies in the canine model raise important translational issues. First, will patients have cones present at the age of treatment? Recent studies combining high-resolution OCT and adaptive optics scanning light ophthalmoscopy have shown that while patients have lower than normal numbers of foveal cones, those remaining likely provide suitable therapeutic targets for gene augmentation.85 Furthermore, a 6- to 26-month short-term longitudinal study of CNGB3-achromatopsia patients reported that the fovea remained structurally stable.85 Secondly, it is still an open question whether the need for CNTF-mediated photoreceptor deconstruction at later stages of the disease is a canine-specific effect or may be required as an adjunct to gene augmentation in human patients. In studies of gene augmentation in sheep with CNGB3-achromatopsia, successful cone functional rescue resulted regardless of the animal’s age at the time of treatment.84 This difference can possibly be explained by the ability of CNGA3, but not CNGB3 subunits, to form functional channels on their own.86

The issue of pretreatment with CNTF prior to CNGB3 augmentation in ongoing clinical trials is not possible or practical, due in part to regulatory issues, but also because one cannot predict a priori which patients, if any, will require such treatment. Pretreatment, however, may not be necessary, as preliminary studies have shown that intravitreal CNTF administered after unsuccessful gene therapy rescues cone function in the mutant dog, and CNTF-Encapsulated Cell Therapy devices are able to effectively deconstruct cone photoreceptors in mutant dogs (Komaromy AM, unpublished observations, 2015). The CNTF ECT device (NT-501 ECT) from

---

**Table 2.** Cone Function Rescue in CNGB3 Mutants After Gene Augmentation Therapy; Effect of Age and Treatment With CNTF Prior to Gene Therapy With AAV5-PR2.1-bCNGB3

<table>
<thead>
<tr>
<th>Studies</th>
<th>No. Eyes</th>
<th>Age, y</th>
<th>CNGB3+/-</th>
<th>CNGB3+/-</th>
<th>Sustained Cone Function Rescue</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study 1</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vector</td>
<td>14</td>
<td>≤0.54</td>
<td>11</td>
<td>3</td>
<td>Yes</td>
</tr>
<tr>
<td>Vector</td>
<td>3</td>
<td>≥1</td>
<td>0</td>
<td>3</td>
<td>No</td>
</tr>
<tr>
<td><strong>Study 2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNTF-vector</td>
<td>7</td>
<td>1.2–3.5</td>
<td>4</td>
<td>3</td>
<td>Yes</td>
</tr>
<tr>
<td>PBS-vector</td>
<td>7</td>
<td>1.2–3.5</td>
<td>4</td>
<td>3</td>
<td>No</td>
</tr>
</tbody>
</table>

Eyes treated with intravitreal CNTF (12 μg in 30 μL PBS) or PBS (30 μL) 1 week prior to subretinal injection of AAV5-PR2.1-bCNGB3 (injection volumes 140–200 μL; dose = 7.96 × 10^14–4.02 × 10^15 vg/ml; the same vector dose was used in pairs of eyes pretreated with intravitreal CNTF or PBS). For additional details, see Table 1 in Ref. 81.
FIGURE 4. Gene therapy outcomes in CNGB3-achromatopsia. (A) CNGB3 mutants with either a missense mutation (\textit{m/m}) or genomic deletion (\textit{\textless\textless}) show normal rod ERG responses, but absent cone responses. Gene therapy restores the cone ERG responses (far right column), and the effect is sustained for at least 2.5 years (B). (C) Cone ERG flicker amplitude increased with higher hCNGB3 transgene expression. Dogs with no recovery of cone function had low levels of transgene expression and were treated with the less robust 3LCR-PR0.5 promoter (red circle, treatment age 8, 23, 28 weeks; green circle, treatment age 60–81 weeks). The optimal PR2.1 promoter resulted in high levels of transgene expression in one dog (blue circle), but no cone function rescue when treatment was done at 54 weeks. Figures 4A–C reprinted from Komaromy AM, Alexander JJ, Rowlan JS, et al. Gene therapy rescues cone function in congenital achromatopsia. \textit{Hum Mol Genet.} 2010;19:2581–2593. © 2010 The Author. Reprinted with permission from Oxford University Press. (D) Photoreceptor deconstruction with CNTF. The relative amounts of retinal bCNGB3 mRNA expression were comparable and not significantly different when subretinal AAV injections were preceded by either intravitreal PBS (no cone function recovery) or CNTF (cone function recovery). (E) In the wild-type retina, CNGA3 and GNAT2 colocalize with L/M opsin in the cone outer segment (top). Gene therapy following intravitreal PBS (middle) fails to correct the mislocalization of CNGA3 and GNAT2 from the outer segment (middle). However, pretreatment with CNTF 1 week prior to gene therapy corrects the mislocalization in the now functional L/M cones (middle). Scale bar: 10 μm. Figures 4D, 4E reprinted with permission from Komaromy AM, Rowlan JS, Corr AT, et al. Transient photoreceptor deconstruction by CNTF enhances rAAV-mediated cone functional rescue in late stage CNGB3-achromatopsia. \textit{Mol Ther.} 2013;21:1131–1141. © 2013 The American Society of Gene & Cell Therapy.
Neurotech (Cumberland, RI, USA) is commercially available and approved for the treatment of macular telangiectasia.

Developing Treatments at Patient-Relevant Disease Stages

Proof-of-principle studies optimize successful outcomes by using animals prior to or during the early disease stages to eliminate confounding disease variables, and determine the optimal vector, promoter, transgene, and dose needed for effective therapy. If treatment fails under these ideal conditions, further preclinical and clinical development of the therapy usually is not warranted unless alternative data from other model systems, for example, cell culture, human induced pluripotent stem cells (iPSCs), are available. Once treatment success is established, optimizing the treatment at patient-relevant disease stages is critical to inform and direct the translational studies that develop the actual treatments. It is at this stage that treatments often fail, either because the model does not recapitulate the essential features of the human disease.
Retinal Gene Therapy

SUMMARY

Gene therapy as a therapeutic modality for treating previously incurable forms of retinal blindness is making great advances since the success of the proof-of-concept studies of canine RPE65-LCA in 2001. The field is still young, but the excitement in both the scientific community and patient advocacy groups has been energizing. I feel fortunate to be part of this therapeutic adventure, and to have collaborated with superb colleagues who continually make this work enjoyable and exciting. Of equal importance, I am proud to have conveyed to the scientific community the importance of the canine model of inherited retinal degeneration as a model for disease gene discovery, for investigating molecular mechanisms of disease, and, most important, for developing therapies to treat human and canine retinal blindness. Such studies truly confirm that dogs are man’s best friend.

Acknowledgments

The author thanks William A. Beltran, Leslie B. King, and Samuel G. Jacobson for critical review of the manuscript and many helpful comments. The author also thanks the scientific collaborators, postdoctoral fellows, graduate students, and technical and support staff whose contributions have been critically important to these studies.

Supported by grants from National Institutes of Health (EY06855, 17549, 19504, P50EY14801, R24EY022012; the author alone is responsible for the content and writing of the paper, and the content does not necessarily represent the official views of the National Eye Institute or the National Institutes of Health), the Foundation Fighting Blindness (Center and Individual Investigator grants), an Alcon Research Foundation Award, and the Van Sloun Fund for Canine Genetic Research.

Disclosure: G.D. Aguirre, P

References


